- |||||||||| Symptom burden in adult survivors of allogeneic hematopoietic stem cell transplantation. (Hall A; Poster Bd # 116) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1194;
These symptoms affect both younger and older patients, although older patients are more likely to have physical impairment. The NCCN Survivorship Assessment Questionnaire captures a number of symptoms related to quality of life and can be more widely utilized as a tool to evaluate survivorship symptoms in patients who undergo HCT.
- |||||||||| Orca-T / Orca Biosystems
Treatment of acute myeloid leukemia with Orca-T. (Hall A; Poster Bd # 111) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1189; P1, P3 This combination of Orca-T with myeloablative BFT led to > 80% RFS without treatment related mortality, and 100% overall survival in this AML patient population. These outcomes were accomplished with consistent and reliable cell manufacturing and distribution of Orca-T at a national scale.
- |||||||||| emavusertib (CA-4948) / Curis, Dr. Reddy's
Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies. (Hall A; Poster Bd # 109) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1187; P1/2 Responders in hrMDS showed lower baseline expression of the NF?B-associated pro-inflammatory gene, IL1?, and lower protein levels in plasma of the angiogenic factor VEGF-A and the chemokine CXCL12. In AML samples, responders have higher baseline levels of VEGF-A, indicating distinct predictive biomarkers for both pathologies.
- |||||||||| TP53 mutation screening for patients at risk of myeloid malignancy. (Hall A; Poster Bd # 105) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1183;
In patients with mutated TP53, co-occurring mutations in GATA2, NF1, BCORL1or RUNX1 at diagnosis were linked to a shorter RFS and indicate a particularly high-risk subgroup that require proceeding to allo-HSCT in CR1 without delay. This study provides generalizable evidence that ultra-sensitive discovery of TP53 mutations prior to cellular therapy is possible and could be a potentially valuable clinical tool to screen for tMN risk.
- |||||||||| Improved overall survival in acute myeloid leukemia over the last 15 years. (Hall A; Poster Bd # 102) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1180;
Improvement in OS is likely multifactorial, including recent drug approvals, increased use of chemotherapy and HCT, and better supportive care. Despite a meaningful improvement in OS, only one out of four patients with AML were alive after five years, highlighting a continued need for further drug development and the importance of HCT.
- |||||||||| Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Evaluation of treatment outcomes with CPX-351 in adults with AML: A meta-analysis. (Hall A; Poster Bd # 99) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1177; Both groups had similar median age, and patients in the CPX-351 arm had longer median overall survival. Our meta-analysis highlights that while CPX-351 achieves CR/HSCT at a higher rate than 7+3, data in younger populations (<60 years old) and patients with de novo AML are sparse.
- |||||||||| Trends in hematopoietic cell transplantation (HCT) in acute myeloid leukemia (AML) from 2004-2019. (Hall A; Poster Bd # 94) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1172;
The increase in HCT utilization from 2004-2010 to 2011-2019, particularly in older adults and those with more comorbidities, may reflect improvement in risk-stratification models, better supportive care, and better management of treatment-related toxicity. However, despite a modest increase in HCT use over the years, significant disparities exist based on race, insurance type, income, and education.
- |||||||||| daunorubicin / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203. (Hall A; Poster Bd # 88) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1166; Excluding patients from S1203 with PS 2-3 or decreased hepatic/renal function would not have prevented treatment-related toxicity. The low rate of protocol therapy discontinuation due to toxicity suggests that eligibility criteria for clinical trials could be further broadened to improve patient access.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Rydapt (midostaurin) / Novartis
Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML). (Hall A; Poster Bd # 84) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1162; We built a suite of predictive models that accurately predict patient response to first-line AML treatment using phosphoproteomic data from routine diagnosis samples. Following validation in independent patient cohorts, this tool will be developed into a single test that predicts treatment response for AML patients, thus addressing an unmet clinical need in this disease.
- |||||||||| PTPN11 variants in chronic myelomonocytic leukemia: Phenotypic and prognostic correlates. (E450b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1150;
The current study identifies PTPN11 and DNMT3A mutations as independent risk factors for both OS and LFS in CMML. In regard to additional genetic risk factors, OS was positively affected by TET2 mutations and negatively by abnormal karyotype, while LFS was negatively affected by ASXL1 mutations.
- |||||||||| prexigebersen (BP1001) - Bio / Path
Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study. (E450b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1148; P2a Since >5 responses are observed in both cohorts, the study will continue with enrollment up to 98 and 54 evaluable pts in cohorts 1 and 2, respectively. Efficacy data are encouraging in a challenging population of frontline adverse-risk, sAML and R/R pts.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
A retrospective comparison of abbreviated course (S100bc) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1143; Palliative care significantly improved rates of discussion and documentation of EOL care preferences, reduced hospitalization at the EOL, and improved QOL in patients with AML and high-risk MDS. We performed a retrospective comparison of patients with newly diagnosed (ND) AML treated with azacitidine (AZA) x 7 days plus VEN x 7 days (
- |||||||||| Clinicians (Hall A; Poster Bd # 273) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1010;
P=N/A The majority of clinicians found it to be a simple and easy way to understand patient values about their care. Clinical trial information: NCT04745676.
- |||||||||| Review, Journal: Association of Leukemia With ABO Blood Group Distribution and Discrepancy: A Review Article. (Pubmed Central) - Apr 24, 2024
The document concludes that studying ABO blood group distributions among leukemia patients showed that the most common blood group in acute leukemia is the A group, while in chronic leukemia, the O group is predominant; more studies are required. This study also confirmed an association between leukemia and ABO blood group discrepancy.
- |||||||||| LP-108 / Lupeng Pharma
Enrollment closed, Combination therapy, Monotherapy: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML (clinicaltrials.gov) - Apr 24, 2024 P1, N=36, Active, not recruiting, We confirmed the tolerability of Japanese and Chinese patients to the dose of quizartinib and chemotherapy regimens used in the QuANTUM-First study. Recruiting --> Active, not recruiting
- |||||||||| LP-118 / Lupeng Pharma
Trial completion date, Trial primary completion date: Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (clinicaltrials.gov) - Apr 23, 2024 P1, N=100, Recruiting, Recruiting --> Active, not recruiting Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Oct 2025
|